1 7 2002 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Himmelsbach et al. 09/914.323

SHAPENO.: Filing Date:

08/24/2001

Title:

4-AMINO-QUINAZOLINE AND QUINOLINE

DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL

TRANSDUCTION MEDIATED BY TYROSINE KINASES 🗸

Docket No.:

5/1252

Commissioner for Patents Washington, D.C. 20231

October 19, 2001

TRANSMITTAL LETTER FOR SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56, copy of International Search Report and

1.97(b). This Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.

The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Alan R. Stempel

Attorney for Applicant(s)

Reg. No. 28,991

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as express mail in an envelope addressed to:

Assistant Commissioner for Patents Washington, DC 20231

on October 19, 2001

By: Alan R. Stempel, Reg. No. 28,991

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT. 06877

Tel.: (203) 798-4868